Orchid Chemicals & Pharmaceuticals Ltd (Orchid) was established in 1992 as a 100% Export Oriented Unit (EOU). Commencing operations in 1994, Orchid has achieved amazing and consistent growth, quantitatively and qualitatively to emerge among the Top-15 companies in the Indian pharmaceutical industry in a short span of fifteen years of operations. Orchid employs over 4000 people, of which over 700 are scientists, technologists and other professionals. Orchid's growth and positioning in the global pharmaceutical industry are indeed distinctive. A robust leadership position in the antibiotics space, a core competence in oral and sterile manufacturing, a broad-based multi therapeutic coverage and an end-to-end connectivity over the pharmaceutical value chain, from discovery to delivery, have positioned Orchid uniquely. Orchid has two manufacturing sites for APIs (at Alathur near Chennai and at Aurangabad, near Mumbai) and three manufacturing sites for Dosage forms (at Irungattukottai and Alathur in Chennai), besides a world-class R&D centre (at Sholinganallur, Chennai). Orchid facilities are state of-the-art and have several international regulatory approvals, including the US FDA and UK MHRA. Orchid API facilities are ISO certified for their quality, environmental management and operational health and safety systems. Orchid has a Joint Venture in China for manufacturing sterile APIs. Orchid scientific and technical strengths have made it a partner of choice for several multinational corporations. Orchid has long-term exclusive marketing alliances with reputed global companies for distribution of its products in the advanced markets.
Orchid has an established end-to-end connected infrastructure for drug discovery and development which are channeled through its subsidiaries, Orchid Research Laboratories in Chennai and Bexel Pharmaceuticals in the US. Through superior infrastructure and by adopting a judicious blend of structure-based drug design approach, Orchid has been able to simultaneously work on several therapeutic programs with several lead compounds in adva2nced stages of trials. Orchid has also entered into Contract Research initiatives with key multinational companies. Orchid is a leader in the use of environment friendly technologies. Orchid has invested substantially in zero-discharge manufacturing processes at its facilities and is considered a national show-case in environmental friendliness.
Indian Subcontinent, South/West Africa, South/West Europe and South East Asia
NEWS
Media Releases 2011 :
Orchid Pharma CMD Mr K Raghavendra Rao awarded the prestigious ‘Padma Shri’ Award by the Government of India
Orchid achieves robust increase in performance during Q3 FY11. Management confident of maintaining strong growth trajectory. Revenue jumps by 33% & PAT zooms by 400%
Orchid Pharma CMD conferred with Icon of the Year Award by ICWAI
Media Releases 2008 :
Orchid receives US FDA approval for Divalproex Sodium DR Tablets
Orchid’s revenue during Q2FY09 rises by 18.7% to Rs 348.45 crore
Achieves salient progress in the Generics and R&D verticals
Orchid receives US FDA approvals for three Cefuroxime Inj. ANDAs
Orchid & Merck & Co., Inc. collaborate to develop novel anti-infective drugs
Orchid to develop Novel Anticoagulant Drug Candidate from Merck
To participate in Diakron which holds the worldwide rights for the compound
Orchid receives EU approvals for Piperacillin Tazobactam injection
Orchid’s Q1 FY09 income grows 30%
Orchid receives Canadian approval for Piperacillin Tazobactam injection
Orchid’s FY08 turnover rises by 36% to Rs 1239 crore
Net profit records a growth of 91%
Ranbaxy and Orchid announce strategic business alliance
To leverage respective strengths for mutually beneficial business growth
Orchid announces the formation of its Japanese Subsidiary, Orchid Pharma Japan KK
To drive foray into the growing high potential Japanese generics market
Orchid Chemicals clarifies on market fall of its shares
Orchid receives US FDA approval for Cefuroxime Axetil ANDA
25th ANDA approval for Orchid
Orchid receives USFDA nod for Granisetron generic formulation
First Indian company to be approved for this non-antibiotic product
Orchid ropes in Dr Gopalan to head its Drug Discovery initiatives
To head Orchid Research Labs as CSO & Director
Orchid’s Q3 FY08 revenue up by 39% to Rs 333 crore
Net profit rises by 91% to Rs 54 crore
Orchid’s formulation facilities receive MCC (South Africa) nod
Processing...
